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Nocturnal Sleep Related with Metabolic Markers in   
End-Stage Renal Disease Patients Receiving Hemodialysis 
 
 
 
ObjectiveaaIt has been suggested that oxidative stress and inflammation are associated with 
the pathophysiology of sleep disorders in end-stage renal disease (ESRD) patients. We ex-
amined the relationship of the sleep variables reflecting sleep breathing disorder and limb 
movements during sleep with the clinical variables reflecting the metabolic abnormalities 
in ESRD patients receiving hemodialysis. 
MethodsaaNocturnal polysomnography was conducted in 30 ESRD patients (21 men, 9 
women), who were receiving hemodialysis. Blood was sampled before hemodialysis for 
each patient in order to measure uric acid (UA), C-reactive protein (CRP), and interleukin 
-6 (IL-6). 
ResultsaaUA was correlated positively with the total sleep time (TST)(r=0.407) and neg-
atively with the apnea-hypopnea index (AHI) and oxygen desaturation index (ODI)(r=  
-0.377, -405). 
ConclusionaaCRP was positively correlated with the limb movement index (LMI)(r=0.401). 
Our study showed that increased UA was related to decreased respiratory disturbance dur-
ing sleep in ESRD patients receiving hemodialysis. 
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Introduction 
 
Sleep problems are very common in patients with end-stage renal disease (ESRD),
as more than 80% of them complain of difficulty in maintaining sleep, restless legs, and
daytime sleepiness.
1 These symptoms could be related to primary sleep disorders such
as sleep apnea (SA), periodic limb movements in sleep (PLMS), or restless legs syn-
drome (RLS). The prevalence of SA in ESRD patients was reported to range from 50
to 70%, which is more than 10 times that of the general population; the prevalence of
PLMS also ranged from 30 to 69%.
2-4 Many factors affect sleep disturbances in ESRD
patients: psychological factors such as depression, anxiety and stress; metabolic fac-
tors related to renal failure such as uremia and anemia; and hemodialysis (HD)-related
factors such as drugs and electrolyte imbalance.
5 
Recently, the increased prevalence of oxidative stress and inflammation in patients
with moderate to severe chronic kidney disease was reported.
6 Oxidative stress and 
acute-phase inflammation may be critical to the pathophysiology of various clinical
symptoms related to ESRD, particularly in the cardiovascular complications that raise
the mortality rate of ESRD patients. 
Similarly, SA has been recognized as an oxidative stress disorder. It has also been 
reported that patients with SA have elevated inflammatory markers such as interleu-
kin-6 (IL-6), tumor necrosis factor (TNF)-α and C-reactive protein (CRP), and have 
a higher risk of cardiovascular disease than the general population.
7 That is, oxidative  
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stress and inflam mation may be associated with the path-
ophysiology of SA in ESRD. Although some studies have 
investigated sleep disorders in terms of the metabolic ab-
normalities in ESRD patients,
2,8 few have investigated 
them in terms of oxidative stress and inflammation. Among 
the metabolic variables related with ESRD, uric acid (UA) 
has not been a significant research topic in previous stud-
ies of sleep disorders in ESRD patients, even though it has 
a strong antioxidant capacity.
9 
We aimed to examine the relationship of the nocturnal 
sleep characteristics linked to sleep breathing disorder 
(SBD) or limb movements during sleep with the levels of 
UA, IL-6 and CRP, which act as metabolic markers re-
flecting the antioxidant capacity or inflammation in ESRD 
patients receiving hemodialysis. 
 
Methods 
 
Subjects 
We studied ESRD patients who were receiving hemo-
dialysis at Kangwon National University Hospital from 
October 2004 until December 2005. 
According to the guidelines of the National Foundation-
Dialysis Outcome Quality Initiative (NKF-DOQI) in Unit-
ed States,
10 ESRD patients were enrolled only when their 
Kt/Vurea (Kt/V) level was above 1.2, reflecting the stabil-
ity of hemodialysis. We excluded subjects with a history 
of psychiatric disease, present psychiatric illness requiring 
treatment, organic brain disease, history of heart failure 
and chronic pulmonary disease, or acute medical illnesses 
such as pneumonia, urinary tract infection, or enteritis, and 
those taking medication affecting sleep. Nine subjects who 
refused to participate in the study were also excluded. 
For 30 ESRD patients, the Epworth Sleepiness Scale 
(ESS)11 and Sleep Disorders Questionnaire (SDQ)12 were 
administered. SDQ was completed for only 16 patients. 
For the remaining 14 patients, SA subscale was adminis-
tered instead of SDQ because of the difficulty completing 
the latter. No subject was found to have a major depres-
sive disorder according to the Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition (DSM-IV),
13 
criteria and based on a clinical interview conducted by a 
psychiatrist. The information on the history of smoking 
and drinking alcohol, current medication, duration of he-
modialysis, and illness preceding ESRD was gathered th-
rough medical records, and the body mass index (BMI) 
was also obtained for each subject. Among 30 patients, 
none had a diagnosis of alcohol abuse or dependence, and 
five were current smokers (Mean pack years±SD=35± 
15.45). Four patients stopped taking sleeping pills for 2 
weeks prior to the sleep study. The study protocol was ap-
proved by our institutional review board, and written in-
formed consent was obtained from each enrolled patient. 
 
Sleep studies 
All subjects were studied by one-night laboratory-based 
polysomnography (PSG). Considering the effect of he-
modialysis on sleep, the PSG (Embla S7000, Medicare-
system, New York, USA) was conducted according to 
each subject’s habitual sleep time one day after hemodi-
alysis. PSG included electroencephalogram (C3-A2, C4- 
A1, O1-A2, O2-A2 by international 10-20 system), chin 
electromyography (EMG), electrooculogram, electrocar-
diogram, snoring, respiratory effort using piezoelectric 
belts over the chest and abdomen, and airflow through the 
nose and mouth using a thermistor. We also recorded bi-
lateral surface EMGs on the legs (with electrodes placed 
over the anterior tibialis muscles). We monitored oxygen 
saturation by pulse oximetry. A polysomnographic tech-
nologist, who had an interrater reliability of more than 
90% with a psychiatrist certified by the American Board 
of Sleep Medicine, manually scored all of the recordings 
for the sleep stages, limb movements, and respiratory ev-
ents by standard techniques.
13 The oxygen desaturation 
index (ODI) was defined as the mean number of events 
per hour in which the oxygen saturation level was decreas-
ed by more than 3% during sleep. Sleep apnea syndrome 
(SAS) was diagnosed when the apnea-hypopnea index 
(AHI) was 5 or greater, and obstructive sleep apnea-hy-
popnea syndrome (OSAHS) when the sum of the obstruc-
tive apnea index (OAI) and hypopnea index (HI) was 5 or 
greater.
15 The limb movement index (LMI) was defined 
as the mean number of limb movements per hour. Limb 
movements immediately following respiratory events 
were not scored. Periodic limb movements (PLMs) were 
defined when more than 4 consecutive limb movements 
with a duration of 0.5-5 seconds were observed every 5-
90 seconds. The periodic limb movement index (PLMI) 
was defined as the mean number of periodic limb move-
ments per hour. A diagnosis of PLMS was made when the 
PLMI was 5 or greater.
15 
 
Laboratory studies 
Blood was sampled for each subject before hemodi-
alysis to measure the UA, CRP, and IL-6 levels. UA was 
measured by the enzymatic method (Denka, Tokyo, Ja-
pan) with a TBA-200FR Chemical analyzer. CRP was 
analyzed by the latex agglutination quantitative method 
(Denka, Tokyo, Japan) with a TBA-200FR device (Toshi-
ba, Tokyo, Japan). IL-6 was measured by enzyme-linked 
immunosorbent assay (ELISA)(Endogen, Woburn, USA). 
The assay ranged from 15-2,450 pg/mL; the intraassay 
and interassay coefficients of variation were below 10%. 
The detection limit of the IL-6 ELISA was 15-20 pg/mL.  
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The indirect indices of protein intake, serum albumin, and 
normalized protein catabolic rate (nPCR){normalized to 
body weight derived from the urea distribution space (Vu-
rea/0.58)} were obtained. For all variables, the values were 
the means of 3 measurements, except for IL-6, which was 
measured once. The IL-6 level was obtained for only 23 
of 30 ESRD patients, because it was not detected in the 
other 7 patients. 
 
Statistical analysis 
Spearman correlation analyses were used to examine 
the relationship between the sleep variables and clinical 
variables of UA, IL-6, and CRP. A Pearson correlation a-
nalysis on nPCR and UA was conducted, considering that 
nPCR is a marker reflecting the nutrition state in ESRD 
patients. All statistical analyses were performed using Sta-
tistical Package for the Social Sciences (SPSS) version 
11.5, and p values below 0.05 indicated statistical signi-
ficance. 
 
Results 
 
Among 30 patients, 15 (50.0%) had diabetes, 8 (26.7%) 
glomerulonephritis, 3 (10.0%) hypertension, and 4 (13.3%) 
unknown diseases as the main causes of ESRD. There was 
no significant difference in any of the sleep variables a-
mong the various groups of patients with different causes 
of ESRD (Kruskal-Wallis test, p>0.05). The prescribed 
drugs were antilipemic agents for 7 patients (23.3%), ACE 
inhibitors for one (0.03%), beta-blockers for 13 (43.3%), 
intravenous iron for 6 (20.0%), and statins for 7 (23.3%). 
The accompanying illnesses were ischemic heart disease 
in 2 patients (6.6%) and left-ventricle hypertrophy in 19 
(63.3%), as well as diabetes in 15 (50%). The demograph-
ic/clinical characteristics and Nocturnal polysomnography 
(NPSG) results are presented in Table 1 and 2, respective-
ly. There was no significant difference in the UA, IL-6 and 
CRP levels between the smoking and non-smoking groups 
(Mann-Whitney test, p>0.05). 
Among 30 patients with ESRD, 28 (93%) were diag-
nosed as having SAS or PLMS; 25 (83.3%) had a diag-
nosis of SAS, 18 (60%) OSAHS, and 18 (60%) PLMS. 
Fifteen patients (50%) had both SAS and PLMS, 13 pa-
tients (43.3%) had both OSAHS and PLMS, and 2 pa-
tients had diagnoses other than the primary sleep disorder. 
Upon reviewing the questions related to RLS in the SDQ 
(Q12. restless legs in falling asleep, Q31. restless legs dis-
turb sleep) for 16 patients who completed it, RLS was di-
agnosed in 5 patients (31%). 
Among the metabolic markers in 30 HD patients with 
ESRD, UA was positively correlated with the total sleep 
time (TST)(r=0.407)(Table 3) and negatively with AHI 
and ODI (r=-0.377, -0.405), and CRP was positively cor-
related with LMI (r=0.401)(Table 4). UA was also signif-
icantly correlated with nPCR (r=0.492, p<0.05). 
 
Discussion 
 
In this study, the proportions of patients with sleep dis-
orders and SAS among 30 ESRD patients were 93.3% 
and 83.3% respectively, which were higher than those of 
previous studies (50-70%).
2,3 Parker et al.
2 showed that 
23 among 46 HD patients (50%) had an AHI above 5, a 
result that seems to differ from ours, for they excluded 
those subjects with SAS, PLMS, or RLS by means of a 
TABLE 1. Demographic and clinical characteristics of end-stage 
renal disease (ESRD) patients receiving hemodialysis (N=30) 
 Mean  (SD) or ratio  Range 
Demographics    
Age (y) 56.13  (10.66) 41.00-86.000 
Sex (m:f)* 21:9   
BMI (kg/m2) 22.57  (03.36) 19.00-32.470 
ESS score  08.79 (05.41)  00..0-22000 
Months on HD  51.20 (34.56)  02.00-131.00 
Laboratory data     
Hemoglobin (g/dL)  09.11 (00.67)  07.80-10.370 
Albumin (g/dL)  03.83 (00.20)  03.47-4.2500 
Phosphate (mg/dL)  04.86 (01.24)  02.83-7.7700 
Uric acid (mg/dL)  07.96 (01.28)  05.53-11.270 
Interleukin-6 (pg/mL)  20.47 (13.07)  07.81-61.950 
CRP (mg/dL)  00.61 (00.83)  00.01-2.8200 
nPCR (g/kg/day)  01.13 (00.24)  00.74-1.7500 
BMI: body mass index, ESS: Epworth Sleepiness Scale, HD: he-
modialysis, CRP: C-reactive protein, nPCR: normalized protein
catabolic rate   
   
TABLE 2. Nocturnal sleep characteristics in ESRD patients re-
ceiving hemodialysis (N=30) 
 Mean  (SD) Range 
TST 362.82  (90.86) 79.00-490.50 
SE  076.53 (20.96) 16.30-97.600 
SL  013.18 (13.12)  00.60-61.500 
S1  019.67 (15.12)  05.20-78.500 
SWS  018.75 (08.91)  00.60-34.600 
REMS  012.34 (06.73)  01.10-23.200 
AHI  024.17 (15.47)  00.70-66.900 
LOS  080.30 (09.55) 59.00-93.000 
ODI  015.48 (12.83)  00.40-50.800 
LMI  054.21 (56.73)  00.90-207.80 
ESRD: end-stage renal disease, TST: total sleep time (min), SE: sleep
efficiency (%), SL: sleep latency (min), S1: stage 1 sleep (%), SWS:
slow wave sleep (%), REMS: rapid eye movement sleep (%), AHI:
apnea-hypopnea index (n/hr), LOS: lowest oxygen saturation 
(%), ODI: oxygen desaturation index (n/hr), LMI: limb movement
index (n/hr)    
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structured interview. Kimmel et al.
3 reported that the pro-
portion of OSAHS patients among those ESRD patients 
with SAS was 56% (9/16), which is lower than 72% (18/ 
25) in the present study: 60% of our ESRD patients were 
diagnosed with PLMS. It has been reported that the in-
cidence of PLMS in ESRD patients is 30-70% in gen-
eral.
2,4 In our study, it is notable that 19 patients (50%) 
had diagnoses of both SAS and PLMS. Previous studies 
have reported either SAS or PLMS separately, except for 
the study of Parker et al.
2 where 12 (26%) of 46 ESRD 
patients had both an AHI and LMI greater than 5. In our 
study, 5 (31%) of 16 ESRD patients who completed the 
SDQ complained of RLS symptoms. In previous studies, 
RLS has been variously reported as affecting 7-60% of 
ESRD patients. Rijsman et al.
16 reported that 58.3% of 
ESRD patients had RLS, and PLMS was found in 90% of 
those with RLS. The RLS with PLMS seems to be clini-
cally important in ESRD patients, since it worsens the 
quality of life.
16 
Increased UA was related to increased total sleep time 
(TST) and to decreased AHI and ODI in our study. Hsu et 
al.
21 recently suggested a positive effect of UA related to 
its antioxidant properties, predicting higher mortality in 
HD patients with lower UA levels. However, UA increases 
in oxidative stress situations such as hypertension, cardi-
ovascular disease, and obstructive sleep apnea (OSA).
17-20 
So, it remains controversial whether serum UA actually 
has antioxidant properties. 
Both OSA
19 and ESRD have been considered as oxi-
dative stress disorders.
6 Although the mechanism related 
to increased oxidative stress could be explained by various 
factors in ESRD patients, the major cause would be the 
retention of oxidized solute by the loss of renal function. 
Supporting our result that increased UA was related to an 
improvement in SBD, UA has been suggested to have an-
tioxidant properties in several studies. Hasegawa et al.
9 
suggested that UA plays an important role as an antioxi-
dant in ESRD patients, and Christou et al.
22 reported that 
UA’s antioxidant capacity was significantly decreased in 
OSA patients with an AHI of more than 20. Our previous 
study also found that increased ODI in SAS was related 
to decreased total antioxidant status (TAS) level, reflect-
ing the antioxidant capacity in ESRD patients.
23 In ESRD 
patients, the association of OSA with a deficit of antiox-
idant capacity may imply that the oxidative stress reaction 
is increased due to the reduced level of cellular reductants 
under a hypoxemic state such as OSA, or the reduced an-
tioxidant capacity results in the occurrence or aggravation 
of OSA. Our study showed that UA levels were signifi-
cantly correlated with the nPCR (r=0.492), reflecting the 
nutritional state of proteins. Söreide et al.
8 reported that 
the intake of branch-chain amino acids (BCAAs) in ESRD 
patients was associated with respiratory stimulation dur-
ing sleep. Malnutrition would also be associated with in-
creased oxidative stress, thus explaining the mechanism 
underlying the relationship between protein nutrition and 
respiration during sleep, although this explanation is not 
conclusive.
24 Therefore, the improvement of SBD may 
be due to the antioxidant properties of UA, reflecting pro-
tein nutrition. 
As the CRP level increased, the LMI increased in our 
study, and there was no sleep parameter correlated with 
IL-6. In ESRD patients, although it was reported that sleep-
iness was induced by the abnormal production of TNF, a 
substance with somnogenic properties,
25 the relationship 
of the sleep variables with inflammatory markers such as 
CRP and IL-6 has not yet been studied. ESRD is recog-
nized as a chronic inflammatory disease, because these 
inflammatory markers are higher in ESRD patients.
6 On 
the other hand, it is known that the metabolic abnormality 
of dopamine can cause an inflammatory reaction,
26 and 
impaired dopaminergic neurotransmission is a major fac-
tor in the pathogenesis of RLS,
27 which is often accom-
panied by increased limb movement (LM) during sleep. 
Accordingly, increased CRP would have been correlated 
with increased LM. However, IL-6, another inflammatory 
marker, was not correlated with LM in our study. This 
could be explained by the instability of the measurement 
of IL-6, since IL-6 was not detected in 7 patients, and the 
IL-6 data were measured only once. Therefore, the rela-
tionship between inflammatory markers and LM in ESRD 
patients cannot be definitively determined from our re-
sults, and further studies will be necessary. 
TABLE 3. Correlations of sleep architecture variables with meta-
bolic markers ESRD patients receiving hemodialysis (N=30) 
  TST SE SL S1  SWS  REMS 
UA  -0.407*  -0.291 -0.201  -0.328 -0.109 -0.317 
IL-6 -0.386* -0.346  -0.287  -0.433 -0.105 -0.200 
CRP -0.031* -0.008  -0.175  -0.245  -0.118 -0.227 
*p<0.05 (Spearman correlation analysis). ESRD: end-stage renal
disease, TST: total sleep time (min), SE: sleep efficiency (%), SL:
sleep latency (min), S1: stage 1 sleep (%), SWS: slow wave sleep
(%), REMS: rapid eye movement sleep (%), UA: uric acid, IL-6: in-
terleukin-6, CRP: C-reactive protein 
 
TABLE 4. Correlations between the variables related with sleep
breathing disorder and limb movements and metabolic markers in
ESRD patients receiving hemodialysis (N=30) 
  AHI LOS ODI LMI 
UA -0.377*  -0.172 -0.405*  -0.024* 
IL-6  -0.328* -0.193 -0.392*  -0.044* 
CRP -0.106* -0.238 -0.217*  -0.401* 
*p<0.05 (Spearman correlation analysis). AHI: apnea-hypopnea
index (n/hr), LOS: lowest oxygen saturation (%), ODI: oxygen de-
saturation index (n/hr), LMI: limb movement index (n/hr), UA: uric
acid, IL-6: interleukin-6, CRP: C-reactive protein 
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The limitations of our study are as follows. First, co-
morbid medical diseases such as hypertension and dia-
betes mellitus were not excluded, since these are relatively 
common in ESRD patients. Since it was also very diffi-
cult to exclude patients taking some form of medication 
(except hypnotics), these substances may have affected 
nocturnal sleep in our study. Second, our results are not 
conclusive, since confounding variables such as age, sex 
and BMI, which affect AHI and LMI, were not controlled. 
Third, we did not conduct multiple sleep studies to reduce 
the first-night effect and ESRD patients with possible pri-
mary sleep disorders were not excluded from our study, 
resulting in the presence of extreme values of the noctur-
nal sleep variables. 
However, a limited number of studies on the relation-
ship between sleep disorder and metabolic markers in 
ESRD patients have been reported. In Asian countries, 
there has only been one study using the sleep question-
naire without conducting NPSG. Considering the recent 
findings that ESRD is recognized as an oxidative stress 
disease or an inflammatory disease, it is meaningful that 
UA was significantly related to decreased severity of SBD, 
and CRP was related to increased severity of LM in our 
study. These findings suggest that UA or CRP levels re-
flect certain sleep disorders in ESRD patients. Further stud-
ies on the relationship of these markers to the pathophys-
iology of sleep disorders are necessary.   
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